Clinical Guideline InSights
The 2026 Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events Scientific Statement and the 2026 Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease Scientific Statement * Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events/Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease * American College of Cardiology * June 30, 2026 * Guideline Summary: https://www.guidelinecentral.com/guideline/5230408/ [https://www.guidelinecentral.com/guideline/5230408/] / https://www.guidelinecentral.com/guideline/5230407/ [https://www.guidelinecentral.com/guideline/5230407/] * Full-Text: https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.033] / https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2 [https://www.jacc.org/doi/10.1016/j.jacc.2026.05.037#tbl2]
57 afleveringen
Reacties
0Wees de eerste die een reactie plaatst
Meld je nu aan en word lid van de Clinical Guideline InSights community!